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Abstract
Turmeric (Curcuma longa L., Zingiberaceae) rhizomes contain two classes of secondary metabolites,
curcuminoids and the less well-studied essential oils. Having previously identified potent anti-
arthritic effects of the curcuminoids in turmeric extracts in an animal model of rheumatoid arthritis
(RA), studies were undertaken to determine whether the turmeric essential oils (TEO) were also joint
protective using the same experimental model. Crude or refined TEO extracts dramatically inhibited
joint swelling (90-100% inhibition) in female rats with streptococcal cell wall (SCW)-induced
arthritis when extracts were administered via intraperitoneal injection to maximize uniform delivery.
However, this anti-arthritic effect was accompanied by significant morbidity and mortality. Oral
administration of a 20-fold higher dose TEO was non-toxic, but only mildly joint-protective (20%
inhibition). These results do not support the isolated use of TEO for arthritis treatment, but, instead,
identify potential safety concerns in vertebrates exposed to TEO.
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INTRODUCTION
Essential oils are complex mixtures of volatile terpenes selected throughout evolution to protect
plants from external threats by various means including mimicking endogenous substrates in
herbivores (1). While biologic and potentially medicinal effects of these essential oils are thus
to be anticipated, these compounds are often less well studied than other classes of secondary
plant metabolites, with polyphenols being a prominent example. Such is the case for turmeric
(Curcuma longa L., Zingiberaceae), a medicinal botanical whose rhizome contains two major
classes of secondary metabolites, the phenolic curcuminoids and the hydrophobic essential oils
(2). Many laboratories, including our own (3,4), have demonstrated potent and physiologically
important effects of the curcuminoids (5). For example, we have elucidated a profound anti-
arthritic effect of curcuminoid-containing turmeric extracts due to their ability to inhibit nuclear
factor-κB (NF-κB) activation in experimental rheumatoid arthritis, thus blocking multiple
downstream signaling pathways critical to joint inflammation, including cyclo-oxygenase
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(COX)-stimulated prostaglandin-E2 (PGE2) production (3). Far less studied, and indeed, often
discarded in the preparation of turmeric dietary supplements (AR), are turmeric's essential oils.
Reported biologic properties of the multi-component essential oils of turmeric include
antifungal (6), mosquitocidal (7), antivenom (8), antibacterial and antioxidant properties (9,
10). Medicinal effects of TEO in vertebrates have also been reported for stroke and diabetes:
a single acute dose of TEO (250-500 mg/kg oral or ip) was neuroprotective in rats subjected
to occlusive or embolic strokes (11-13), while chronic TEO dietary supplementation (≥620
mg/kg/d) normalized serum glucose in diabetic mice (14,15).
Major compounds present in turmeric essential oils (TEO) include ar-turmerone, α-turmerone
and β-turmerone. The relative proportions of these terpenoids in TEO extracts vary depending
on the rhizome's geographic origin and method of extraction (9,16,17). In isolation, these
compounds have demonstrated bioactivity in vitro, including cytotoxic and apoptotic effects
in various cells (18,19); binding to the nuclear receptor, peroxisome proliferator-activated
receptor γ (PPAR-γ) (14); inhibition of inducible PGE2 and NO production (2,20); and
inhibition of platelet aggregation (21).
Emerging in vitro evidence from our laboratories and others suggests that crude, multi-
component hexane extracts of TEO may be more bioactive than any of their individual fractions
or components (2,9,11). For example, when our laboratories isolated and compared the efficacy
of 8 distinct fractions of a crude TEO extract vs. the extract itself in blocking COX-mediated
PGE2 production in vitro, the potency of the crude TEO extract exceeded that of each of its
fractions (2). Moreover, the crude essential oils had the same potency as turmeric's other
secondary metabolites, the curcuminoids, in this in vitro screening assay. Thus, we have
postulated that the essential oils of turmeric may also have significant medicinal anti-arthritic
effects in vivo--independent of those attributed to turmeric's polyphenols—that result from
synergistic actions of the oil's various constituents.
To test this postulate, in vivo studies described herein were undertaken to determine whether
the essential oils of turmeric are indeed effective anti-arthritic agents using an animal model
of rheumatoid arthritis (RA), streptococcal cell wall (SCW)-induced arthritis. Because we
previously used this model to characterize anti-inflammatory properties of essential-oil free,
curcuminoid-containing turmeric extracts (3,4), these experiments also allowed us to compare
the relative in vivo anti-inflammatory efficacy of each of turmeric's two major classes of
secondary metabolites. Moreover, our isolation and in vivo testing of two complex TEO
extracts, a crude hexane extract and a curcuminoid-stripped, refined fraction of the crude TEO
extract, also allowed for clarification of the independent role of the essential oils (vs.
curcuminoids) in preventing intra-articular inflammation.
MATERIALS AND METHODS
Turmeric Essential Oil Preparation
Turmeric essential oil (TEO) extracts were isolated from dry turmeric rhizome powder as
described in detail in United States Patent 7,205,011. In brief, a crude TEO extract was prepared
from 1 kg dry Curcuma longa L., Zingiberaceae rhizome powder (San Francisco Herb, SF,
CA) by n-hexane extraction at room temperature for 24 hours. The resultant mixture was
filtered, the filtrate was combined with an n-hexane wash of the marc, and the solvent was
stripped under vacuum for 24 hours to obtain a crude turmeric oil extract (yield, 3.7%). HPLC
analysis revealed minor curcuminoid contamination of this essential oil-enriched extract. The
crude TEO (36g) was processed further by silca gel column chromatography. Elution was by
the gravity method. The column was eluted with n-hexane (100%). Fractions (25-30 mL each)
were collected until the color of the eluant changed from colorless to yellow to colorless again.
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The column was then eluted with a mixture of n-hexane and ethyl acetate (17:1 v/v) for a total
of 15 L. The column was finally leached with 100% ethyl acetate (1 L) and elution was
discontinued. The solvent from the 15 L fraction was stripped off under vacuum using a rotary
evaporator, and the resulting refined TEO was then left under vacuum for a minimum of 24
hrs (66-74% yield, by weight).
Chemical Analysis of Turmeric Essential Oil Extract
The major components of crude and refined TEO extracts were characterized chemically by
GC-MS and HPLC. Identification of the three major constituents of the essential oils was
achieved by comparison of their mass spectral fragmentation patterns (NIST08 database/
WorkStation data system) and with literature reports (22,23). GC–MS data were recorded with
a Varian Saturn 2100T (Palo Alto, CA). The gas chromatograph was fitted with a Chrompack
capillary column (CP Sil 8 CB; 30 m × 0.25 mm). Operating conditions: column oven
temperature programmed at 80 °C for 5 min and then to 280 °C at 10 °C/min; injector/transfer
line/trap temperatures 250/250/200, respectively; electron voltage, 50–80 eV. UHP helium was
used as the carrier gas at a flow rate of 1.2 mL/min. Each sample (1 mg) was dissolved in
CH2Cl2 (0.5 mL) and injected (1 μL) directly into the chromatograph.
The HPLC system for extract analysis was composed of the following: Agilent 1100 series
with a quaternary pump, a degasser, a thermostated column compartment, a thermostated
autosampler, a diode array detector and ChemStation for LC 3D, Rev. A.09.03 (1417) software
for system control and data acquisition (Agilent Technologies Inc., Palo Alto, CA). The
samples (20 μL) were injected onto a Synergy, 4m, Hydro-RP 250 × 4.6 mm column coupled
with SecurityGuard AJO-4287 guard column (Phenomenex, Torrance, CA). The mobile phases
used were as follows: A: 500 μL acetic acid/L of Nanopure water; B: 500 μL acetic acid/L of
acetonitrile. The organic mobile phase was filtered through a 0.2 μm PTFE membrane filter
and the water based mobile phase was filtered through a 0.2 μm cellulose nitrate. The mobile
phases were thoroughly degassed before analysis and throughout the analysis. The eluent was
monitored at 425 nm, 370 nm, 280 nm and 250 nm; the flow rate was 1 mL/min. For HPLC
analysis, triplicates of approx. 1-2 mg sample were weighed using analytical balance, dissolved
in a small volume of dichloromethane then completed to volume with methanol (5:95) with
final concentration of approximately 1 ppm. Solutions were transferred into an amber
autosampler vials and 3 × 20 μL was injected onto the HPLC column.
SCW-induced Arthritis and Dosing Regimes
All animal experiments were performed in compliance with the University of Arizona
Institutional Animal Use and Care Committee (IACUC). To induce arthritis, female Lewis rats
(110 g, Harlan, Indianapolis, IN) were injected ip with peptidoglycan-polysaccharide polymers
(25 μg rhamnose/g body weight) isolated from the sonicated cell wall of Group A Streptococcus
pyogenes (SCW) (Lee Laboratories, Grayson, GA) or normal saline (vehicle) (3,24).
Intraperitoneal (ip) or oral (po) administration of TEO extracts or the appropriate vehicle (0.5
μL DMSO/g for ip dosing or 0.5 μL 8% saccharine in DMSO/g for oral dosing) began 4 days
before, or 3 days after, SCW injection, as indicated (4). Daily dosing continued until acute
inflammation subsided (10 days post-SCW), at which time frequency was decreased to 5 days/
week. Oral dosing was maintained at this level until the end of the experimental period, while
ip dosing during the final week decreased again to thrice weekly due to increasing evidence of
toxicity. Treatment groups for arthritis experiments thus included 1) 2 normal animals treated
with vehicle; 2) normal animals treated with TEO extracts; 3) SCW-injected arthritic animals
treated with vehicle; and 4) SCW-injected arthritic animals treated with TEO extracts.
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Joint inflammation was determined in a blinded fashion by daily assessment of arthritic index
(AI) in each distal limb using standard criteria (3,24) (0 = normal; 1 = slight erythema and
edema; 2 = increased edema with loss of landmarks; 3 = marked edema; 4 = marked edema
with ankylosis on flexion, for a total possible score of 16/animal).
Real time RT PCR
RNA was isolated from hind ankle joints as previously described (3). Equal amounts of RNA
were combined from 3 (non-arthritic) or 3 (arthritic) joints/treatment group to make one sample.
Three such pooled RNA samples/treatment group (i.e. total of 9-12 joints analyzed per group)
were used for analysis of articular mRNA expression using real-time RT-PCR TaqMan®
analysis and previously described methods (3). Rat specific primers for interleukin 1 beta
(Il-1ß) (Rn00580432_m1), monocyte-chemotactic protein 1 (MCP-1) (Rn00580555_m1),
growth-related oncogene/keratinocyte chemoattractant (GRO/KC) (Rn00578225_m1),
cyclooxygenase 2 (COX-2) Rn00568225-m1), mannan-binding lectin serine peptidase 1
(Rn00434830_m1), properdin (Rn01526084_g1), and an 18S primer (as an internal control;
Hs99999901_s1) were obtained from Applied Biosystems (Foster City, CA). Data, normalized
to the endogenous reference (18S RNA), were analyzed using the comparative CT method as
previously described (3).
Toxicity
To monitor for possible toxic effects of TEO treatments in normal or SCW animals, daily
weights and mortality were assessed. Liver and renal function were monitored by assay of
alanine aminotransferase (ALT) and creatinine levels in blood samples obtained at the indicated
times after injection of SCW (or vehicle) using a Hemagen Diagnostics Endocheck Plus
Chemistry Analyzer (Columbia, MD). Circulating white blood cell counts, hematocrit and
platelet counts in whole blood were also determined using a Hemavet 880 analyzer (CDC
Technologies, Oxford, Conn.). Necropsies, including histologic assessment of all organs, were
performed in a blinded fashion by a veterinary pathologist. Occult blood in stools was assessed
by Hemocult testing (VWR, West Chester, PA).
Histology
Liver tissue specimens were fixed in 10% formalin and subsequently embedded in paraffin.
SCW-induced hepatic granuloma formation at day 28 was assessed in H&E stained liver
sections using standard criteria and blinded analysis (3,24).
Statistical Analysis
Values are presented as mean ± SEM except where indicated. Accumulative effects of
treatment on joint swelling were determined by assessing area under the curve (AUC) for each
animal (25). Statistical significance was determined by ANOVA with post hoc testing,
Student's t-test or by Fisher's exact test, as indicated, using InStat software (GraphPad Software,
San Diego, CA).
RESULTS AND DISCUSSION
Isolation and Characterization of major components in TEO Extract
HPLC analysis of the crude hexane extract prepared from powdered turmeric rhizomes (3.7%
yield) revealed slight contamination of the oils by the 3 major curcuminoids (curcumin,
demethoxycurcumin, and bisdemethoxycurcumin) with retention times less than 25 minutes,
as well as the presence of 3 major peaks with retention time more than 25 minutes. Column
fractionation of the crude TEO extract resulted in a second, refined extract (66% yield). In the
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refined TEO, the relative ratios and content of the 3 major terpenoids were retained, while
curcuminoids where no longer detectable (Figures S1 and Figure S2). GC-MS data (the
retention time order, the MS fragmentation pattern) of these 3 major peaks were compared
with NIST08 library and with those published of turmeric essential oils (22, 23). This resulted
in the identification of the three major HPLC peaks as: ar-turmerone, α-turmerone and β-
turmerone (Figure S1 A-G). These two experimental TEO extracts were then tested in vivo.
Antiarthritic Effects of Intraperitoneal TEO Extracts
To assure uniform delivery of the two experimental extracts while establishing and comparing
their anti-arthritic bioactivity, TEO extracts were administered ip to maximize delivery and
eliminating any potential confounding effects of differential gastrointestinal absorption. Doses
of the crude TEO were normalized based on the 66% yield of the refined extract and are
expressed as mg equivalents of refined TEO (e.g. 86 mg crude × 0.66 = 56 mg equivalents of
refined). Using this approximation, differences in bioactivity for a given normalized dose of
crude vs. refined TEO can be attributed to the additional components present only in the crude
extract. Treatment with either TEO extract (56 mg equivalents of refined/kg/d) beginning prior
to SCW injection, profoundly inhibited joint swelling (95-100% inhibition) in animals with
SCW-induced arthritis (Figure 1A). This marked degree of inhibition by turmeric's essential
oils is comparable to that previously demonstrated by our laboratories for an equivalent dose
of turmeric's other secondary metabolites, the curcuminoids (3). Indeed, this extract dose was
specifically chosen as a starting point for determining TEO's anti-arthritic efficacy based on
our previous findings with the curcuminoids. When start of TEO treatment was delayed until
after the peak in acute inflammation (day 3), the essential oils were also protective (Figure 1B),
although to a lesser degree (64%). These findings are again consistent with results we obtained
previously in this model when evaluating curcuminoid-only turmeric extracts (3). Dose-
dependent inhibition of arthritis was similar for the crude vs. refined TEO (ID50 approximately
10 mg equivalents of refined TEO/kg/d) during the initial acute phase (day 3) of joint swelling
(Figure 2A), as well as the later, chronic phase of articular inflammation (day 28) when erosion
of articular cartilage and bone occurs (Figure 2B). These data suggest that additional
components present only in the crude TEO, including, but not limited to, the very low levels
of curcuminoids, were not likely to have additive or synergistic anti-arthritic effects with
turmeric's purified essential oils. In totality, then, our data suggest that each class of secondary
metabolites in turmeric, the essential oils and the curcuminoids, can act independently and with
similar efficacy and potency to block arthritis using this experimental model and mode of
delivery (ip).
In addition to examining the clinical endpoint of joint swelling, inhibitory effects of TEO on
articular inflammation were confirmed at the molecular level by assessing the activation of
genes critical to articular inflammation. The early induction of chemokines responsible for the
intra-articular recruitment of inflammatory cells (the neutrophil chemokine, GRO/KC, and
monocyte chemokine, MCP-1), and of key inflammatory cytokines (IL-1beta), was prevented
by TEO treatment. Similarly, activation of an additional arm of the innate immune response,
antibody-independent complement pathways (induced expression of mannose binding lectin
and properdin) (26), and the inducible expression of other downstream mediators of joint
inflammation, such as COX-2, was blocked in the joints of SCW-injected animals treated with
TEO (Table 1).
Extra-articular Anti-inflammatory Effects of Intraperitoneal TEO Extracts
Anti-inflammatory effects of TEO were not limited to the joints. TEO also blocked SCW-
induced leukocytosis and the granulomatous inflammatory response that occurs at sites of
hepatic SCW deposition (4,24) (Table 2). As with arthritis inhibition, these extra-articular anti-
inflammatory effects were dose-dependent, occurring only with TEO doses ≥ 28 mg/kg/day
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(data not shown). However, unlike the equipotent effects of refined and crude TEO on articular
inflammation, the crude TEO was more effective in blocking nonarticular inflammation (Table
2), suggesting that the additional components present only in the crude extract were also
bioactive with independent and/or synergistic anti-inflammatory effects.
Toxicity Associated with Intraperitoneal TEO Extracts
Joint-protective and/or anti-inflammatory effects of ip TEO were associated with an extremely
high rate of mortality. Significant numbers of normal and SCW-injected animals treated ip
with ≥ 28 mg/kg/d TEO began to die after 2 weeks of treatment (Figure 3), resulting in a
mortality rate of 20% (crude) or 36% (refined) by the end of the month-long experimental
period. In contrast, no deaths occurred in animals (control or SCW-injected) treated with
vehicle or lower TEO doses (≤ 2.8 mg/kg/d) that were without evidence of anti-inflammatory
effects (data not shown). Notable findings in those animals that survived one month of ip
treatment with ≥ 28 mg/kg/d TEO included elevations in serum alanine aminotransferase
(ALT), consistent with hepatocellular damage, that was more notable in crude TEO survivors
(Table 2 and Figure 4A). In addition, control animals treated with either TEO were anemic
(Table 2 and Figure 4B), while the anemia that occurs in SCW-injected animals, which is
typically reversed with effective anti-arthritic treatment (3) neither improved nor worsened
with anti-inflammatory doses of TEO (Table 2). In contrast to these adverse effects, there was
no evidence of damage to the kidneys (Table 2), a primary site of clearance of terpenes and
their metabolites (27), in surviving animals.
To eliminate survivor bias and identify the time of onset of TEO-induced anemia and
hepatotoxicity, toxicity screening was performed as a function of time in control animals treated
with the TEO extract causing the highest mortality (refined TEO, 56 mg/kg/d ip). Anemia
(Figure 5A) and elevations in ALT (Figure 5B) began at 2 weeks, a time co-incident with the
onset of mortality in arthritis treatment experiments (Figure 3), thus suggesting possible
causality. While elevations in circulating leukocytes (WBC) (Table 2) and platelets (PLT) (data
not shown) were not detected in non-arthritic animals surviving one month of TEO treatment,
both of these indicators of systemic inflammation began to increase after 2 weeks of TEO
administration (Figure 5C&D), consistent with an inflammatory response to ip administration
of the essential oils.
Evidence of occult gastrointestinal bleeding as a cause of anemia was sought in animals treated
with ≥ 28 mg/kg/d TEO vs. vehicle. On random screening, occult blood was documented in
the stools of 38% of crude TEO-treated animals (n = 16, p < 0.05 vs. vehicle [9% incidence,
n = 22]) and 19% of those treated with refined TEO (n= 32, p > 0.05 [non-significant]).
Necropsies performed after 2-4 weeks of treatment with TEO ≥ 28 mg/kg/d (n = 2, crude TEO;
n = 4, refined TEO) were notable for signs of mild to moderate peritonitis, including evidence
of a small intestine perforation in one crude TEO treated animal. In contrast, vehicle-treated
animals (n = 2) had no peritonitis and necropsies were only notable for granulomatous lesions
in the liver in those animals also injected with SCW. There was no evidence of renal toxicity
on necropsy. In sum, effective anti-arthritic doses of both TEOs, when administered ip, were
also associated with peritonitis, gastrointestinal bleeding with anemia, and hepatocellular
damage.
Oral TEO Extract Dosing: Toxicity and Anti-inflammatory Effects
The above findings beg the question of whether the toxic effects of both TEOs were specific
to their ip route of administration. Additionally, it is possible that the anti-inflammatory effects
of TEO when administered ip were non-specific and simply due to TEO-induced peritonitis
inducing tolerance to the SCW (28). To address both questions, oral TEO dosing studies were
undertaken. TEO doses (560 mg/kg/d) 20-fold higher than the lowest effective ip doses of
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crude or refined TEO were arbitrarily chosen for testing since minimal information is available
regarding oral absorption and bio-disposition of essential oils or their terpene components
(27). No mortality (data not shown), evidence of hepatocellular damage (Figure 4C), anemia
(Figure 4D), or occult gastrointestinal bleeding (n = 4-5 animals screened per treatment)
occurred after one month of daily oral administration of crude or refined TEO. No peritonitis
was seen on necropsy (n = 1 animal per treatment). However, proteus bacteria was detected in
the abdominal cavity of the crude TEO treated anima examined, suggesting the possibility of
an otherwise undetected intestinal perforation vs. accidental specimen contamination.
Having verified the relative absence of toxicity with oral (vs. ip) administration of TEOs, the
oral anti-inflammatory activity of crude TEO, the extract having the greatest range of articular
and extra-articular anti-inflammatory effects when administered ip, was assessed in the SCW
model. Oral treatment with crude TEO (520 mg/kg/d), begun prior to SCW administration
(Figure 6A), or after the peak of acute joint inflammation (Figure 6B), decreased joint swelling
at every time point. This anti-inflammatory effect, when analyzed on a daily basis, was only
statistically significant at the start of pre-treatment (Figure 6A, day 1). However, assessment
of joint inflammation by analysis of the area under the curve (AUC) during the entire course
of TEO treatment demonstrated a relatively modest but statistically significant 21% inhibition
of joint swelling in response to early or delayed oral crude TEO treatment (p < 0.02 vs. vehicle).
In contrast to this joint protective effect of oral crude TEO, and in contradistinction to the
articular and extra-articular anti-inflammatory effects of this extract when administered ip,
SCW-induced leukocytosis or hepatic granulomatous inflammation were unaltered by oral
crude TEO (data not shown).
In sum, oral crude TEO, at a dose that would correspond to 5000 mg/d in humans after
correcting for body surface area (29), has a modest anti-inflammatory effect in rats that was
limited to the joints and appeared to be specific in that it was not associated with evidence of
significant concurrent toxicity. However, the clinical relevance of this finding is unclear given
the magnitude of the dose required to achieve a relatively modest effect. One limitation of this
study, then, is the absence of an oral dose response. However, reported side effects in 2 of 9
human subjects treated orally with a 50-fold lower dose of TEO in a prior human trial, including
possible reactivation of tuberculosis (17), calls into question the safety and practicality of
administering TEO doses higher than, or indeed equivalent to, those tested here.
Not specifically tested in these studies are possible additive or synergistic joint-protective
effects of TEO when combined with curcuminoids, the other class of turmeric rhizome
secondary metabolites. Previous reports of enhanced bioavailability of curcumin when
administered orally with TEO terpenes (30) suggest that the combined administration of these
two secondary metabolites of turmeric may be clinically useful due to matrix effects
independent of any separate biological activity of the essential oils. However, it must also be
stated that the safety of long term use of dietary supplements containing higher doses of TEO
and/or curcuminoids than those typically consumed with culinary intake (e.g. 4 mg/kg/d
curcuminoids or TEO in a typical Indian diet, given the 3% yield of curcuminoids (4) or TEO
from dried rhizome), remains to be investigated. The toxic effects of turmeric essential oils
when administered ip in these studies should remain a cautionary finding.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
ALT serum alanine aminotransferase
ANOVA analysis of variance
COX cyclooxygenase
d day
GRO/KC growth-related oncogene/keratinocyte chemoattractant
HCT hematocrit







SCW streptococcal cell wall
SEM standard error of the mean
TEO turmeric essential oils
TNF tumor necrosis factor
WBC white blood cell
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Effects of ip turmeric essential oil (TEO) extracts on joint inflammation. Female Lewis rats
were injected on day 0 with vehicle or streptococcal cell wall (SCW, 25 ug/g body weight) to
induce arthritis. Joint swelling in limbs was assessed at indicated times and expressed as mean
arthritic index (AI) (scale 0-3/limb for total possible score of 16/animal) with statistical
significance determined by analysis of variance with post hoc testing or Mann Whitney (n =
4-7 animals/group). A. Intraperitoneal treatment with crude or refined TEO (normalized to 56
mg refined TEO/g) or vehicle was begun 4 days prior to SCW injection and continued daily
until 10 days after SCW injection, at which time dosing frequency decreased to 3-5 days per
week. * p < 0.05 for refined or crude TEO (vs. vehicle). ** p < 0.10 for refined or crude TEO
Funk et al. Page 11













(vs. vehicle). § p < 0.05 for crude TEO only (vs. vehicle), ¶ p < 0.05 for refined TEO only (vs.
vehicle). B. Intraperitoneal treatment with crude TEO (normalized to 56 mg refined TEO/g)
or vehicle was delayed until 3 days after SCW injection and continued daily until 10 days after
SCW injection, at which time dosing frequency decreased to 3-5 days per week. * p < 0.05 for
crude TEO (vs. vehicle).
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Dose-dependent inhibition of joint swelling by ip TEO extracts. Female Lewis rats were
injected on day 0 with vehicle or streptococcal cell wall (SCW, 25 μg/g body weight) to induce
arthritis. Intraperitoneal treatment with crude or refined TEO (with indicated extract doses,
beginning as low as 0.28 mg/kg/d, normalized to refined TEO), or with vehicle, was begun 4
days prior to SCW injection and continued daily until 10 days after SCW injection, at which
time dosing frequency decreased to 3-5 days per week. Arthritic index was assessed in TEO-
treated and vehicle-injected animals and is expressed here as percent inhibition relative to
controls (n = 5-30/group) with * p < 0.01 vs. untreated. A. TEO inhibition of initial, transient
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joint swelling (day 3). B. TEO inhibition of joint swelling during chronic, joint-destructive
phase (day 28).
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Mortality in Animals Treated with ip TEO. Survival in all animals (SCW or control) treated
ip with ≥ 28 mg/mg/d refined (n = 62) or crude TEO (n = 90) vs. vehicle (n = 86) was analyzed
by log-rank using Kaplan Meier survival curves. Mortality was significantly (p < 0.0001)
increased in animals treated ip with either crude or refined TEO extract as compared with
vehicle.
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Hepatotoxicity and anemia associated with ip vs. oral TEO. A. Effects of ip treatment (≥ 26
mg/kg/d) with crude TEO (n = 32) or refined TEO (n = 54) vs. vehicle alone (n = 48) on serum
levels of alanine aminotransferase (ALT) were determined in SCW or control animals
surviving 23-32 days of treatment. Means are not statistically different by ANOVA. B. Effects
of ip treatment with crude TEO (n = 18) or refined TEO (n = 37) vs. vehicle alone (n = 29) on
hemacrit (HCT) were determined in control animals surviving 23-32 days of treatment. p <
0.001, crude vs. vehicle. p <0.01, refined vs. vehicle. C. Effects of oral treatment (> 560 mg/
kg/d) with crude TEO (n = 34) or refined TEO (n = 5) vs. vehicle alone (n = 23) on serum
levels of alanine aminotransferase (ALT) were determined in SCW or control animals
surviving 28-32 days of treatment. p <0.01, refined vs. vehicle. D. Effects of oral treatment (>
560 mg/kg/d) with crude TEO (n = 11) or refined TEO (n = 5) vs. vehicle alone (n = 6) on
HCT were determined in control animals surviving 28-32 days of treatment. p <0.01, crude vs.
vehicle.
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Time course of adverse effects of ip treatment with refined TEO on liver and hematopoetic
parameters. In normal female Lewis rats, the effect of daily ip treatment with 28 mg/kg/d
refined TEO vs. vehicle was determined over a 23-day period. Animals (n = 3 vehicle and n =
4 TEO) were sacrificed at the indicated times for assessment of hematologic parameters
(hematocrit [HCT], total white blood cell [WBC], and platelet [PLT] counts) and liver function
(serum levels of alanine aminotransferase) as well as gross necropsy which was notable for
peritonitis, beginning as early as day 8. Results are presented as mean ± SEM.
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Effects of oral crude TEO extract on joint inflammation. Female Lewis rats were injected on
day 0 with vehicle or streptococcal cell wall (SCW, 25 μg/g body weight) to induce arthritis.
Joint swelling in limbs was assessed at indicated times and expressed as mean arthritic index
(AI) (scale 0-3/limb for total possible score of 16/animal) (n = 4-8 animals/group). A. Oral
treatment with crude TEO (normalized to 560 mg refined TEO/kg/d) or vehicle was begun 4
days prior to SCW injection and continued daily until 10 days after SCW injection, at which
time dosing frequency decreased to 5 days per week. * p < 0.05 for crude TEO (vs. vehicle).
B. Oral treatment with crude TEO (normalized to 560 mg refined TEO/kg/d) or vehicle was
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delayed until 3 days after SCW injection and continued daily until 10 days after SCW injection,
at which time dosing frequency decreased to 5 days per week.
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